Progressive multiple sclerosis, cognitive function, and quality of lifeHelene Højsgaard Chow, Finn Sellebjerg, Melinda Magyari et al.|Brain and Behavior|2018Cited by 94
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trialKaren Schreiber, Per Soelberg Sørensen, Finn Sellebjerg et al.|Multiple Sclerosis Journal|2016Cited by 53
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sørensen, Melinda Magyari, Alex Heick et al.|Multiple Sclerosis and Related Disorders|2022Cited by 42
NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosisCecilie Ammitzbøll, Finn Sellebjerg, Melinda Magyari et al.|Multiple Sclerosis and Related Disorders|2023Cited by 13
Disability in progressive MS is associated with T2 lesion changesCecilie Ammitzbøll, Finn Sellebjerg, Ellen Garde et al.|Multiple Sclerosis and Related Disorders|2017Cited by 10